Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

DARK SECRETS: 3 | Rare Historical Photos

Should You Buy This Blue-Chip Dividend Stock at Record Highs?

AbbVie shares have hit record highs after extending Rinvoq’s patent protection to 2037, boosting confidence in future earnings and dividend growth, with analysts seeing steady fundamentals and modest upside as the company’s immunology pipeline drives results.

Barchart

The 5 Best Dividend Stocks to Buy for Steady Income in 2025

Here are five “set-and-forget” dividend stocks.

Barchart

Why Is AbbVie Stock Trading Higher On Thursday?

AbbVie Inc. (NYSE:ABBV) stock is trading higher on Thursday following an SEC filing that settled litigation with all generic manufacturers, which filed abbreviated new drug applications with the U.S. Food and Drug Administration for generic versions of upadacitinib tablets, marketed by the company as Rinvoq.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Is AbbVie Stock Underperforming the S&P 500?

AbbVie has underperformed the S&P 500 over the past year, but analysts are cautiously optimistic about the stock’s prospects.

Barchart

These 2 Healthcare Stocks Are Even Better Bargain Buys Than UnitedHealth

As the healthcare sector lags broader markets, AbbVie’s innovation in immunology and Johnson & Johnson’s MedTech expansion make these dividend giants standout bargains at below-market valuations

Barchart

As the Market Rotates, This Healthcare ETF Is Leading the Way

Health care saw some of the worst losses this year. But as the calendar turned to August, it's been leading the market higher. This ETF provides exposure.

MarketBeat

AbbVie Strikes $1.2 Billion Agreement For Next-Gen Psychedelic Depression Treatment

AbbVie Inc. (NYSE:ABBV) announced Monday that it will acquire Gilgamesh Pharmaceuticals Inc.’s lead investigational candidate for moderate-to-severe major depressive disorder (MDD).

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Tesla's Quality Score Tumbles, While Taiwan Semiconductor's Growth Rating Soars

While daily stock price moves tend to dominate headlines, shifts in fundamental ranking scores can often tell a deeper story about a company's trajectory. This week, Benzinga's proprietary Growth, Value, Quality and Momentum data revealed major swings among household names, from electric vehicles to pharmaceuticals and financials.

Benzinga

AbbVie's Patch Baldness Study Finds High Hair Coverage Rates With Investigational Drug Upadacitinib

AbbVie Inc. (NYSE:ABBV) on Thursday released topline results from the second of two pivotal studies of the Phase 3 UP-AA clinical program evaluating the safety and efficacy of upadacitinib (RINVOQ; 15 mg and 30 mg, once daily) in adult and adolescent patients with severe alopecia areata (AA) with a mean…

Benzinga

Sixth Circuit Rejects Associational Standing in Medicare Drug Pricing Challenge

An easy way to avoid the merits in the latest high-stake health care litigation.

Reason

AbbVie Inclusion In Medicare Drug Talks Fails To Justify Lawsuit, Court Rules

AbbVie Inc. (NYSE:ABBV), the manufacturer of Imbruvica, is at the center of a constitutional challenge to the federal government's new Drug Price Negotiation Program.

Benzinga

AbbVie Stock Outlook: Is Wall Street Bullish or Bearish?

Despite AbbVie’s underperformance relative to the S&P 500 over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

Barchart

AbbVie Soars On Skyrizi And Rinvoq Strength, Outpacing Humira Erosion

On Thursday, AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 billion.

Benzinga

5 Dividend Stocks With Solid Returns And More Growth Ahead

Sector by sector, U.S. dividend stocks have outperformed so far this year, with historically dividend-friendly industries surpassing those with a more growth-oriented focus.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

AbbVie Stock Eyes Breakout as Pipeline and Profits Grow

AbbVie stock pops after strong Q2 earnings and raised guidance, as Skyrizi and Rinvoq offset Humira's decline and support a bullish outlook

Benzinga

AbbVie Lifts Outlook, Eyes Parkinson's Assets As Next Growth Frontier

AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 billion. Sales increased 6.6% on a reported basis or 6.5% on an operational basis. The company reported adjusted earnings of $2.97, up 12.1% year over year and missing the consensus of $3.23.

Euronews

Seven all-American products that are actually 'Made in Europe', set to be hit by US tariffs

Trump’s tariffs are aimed at ostensibly boosting US production and fostering a “local for locals” sensibility. Except, it turns out that several American product staples are actually... "Made in Europe"?

Benzinga

Uber, Western Union, Live Nation Entertainment And A Health Care Stock On CNBC's 'Final Trades'

As investors navigate a volatile market landscape, attention turns to upcoming earnings reports from major companies, which could provide insights into broader economic trends. This earnings season, analysts and investors are closely watching key players like AbbVie, Uber, and Western Union for signs of growth and stability amid shifting market…

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Boeing, Joby Aviation, Oracle And A Health Care Stock: CNBC's 'Final Trades'

The investment landscape is shifting as companies across various sectors demonstrate resilience and innovation, prompting investors to reassess their portfolios.

Benzinga

Why Is AbbVie Stock Trading Higher On Thursday?

IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation Inc., and AbbVie Inc. (NYSE:ABBV), on Thursday, announced an exclusive licensing agreement for IGI’s lead investigational asset, ISB 2001, developed using IGI’s proprietary BEAT protein platform, for oncology and autoimmune diseases.

Barchart

Here's What to Expect From AbbVie's Next Earnings Report

AbbVie will release its second-quarter earnings later this month, and analysts anticipate a double-digit bottom-line growth.

Barchart

3 Giant Dividend Stocks to Buy to Shield Your Portfolio Now

These dividend stocks provide consistent income and long-term stability.

Barchart

3 Dividend Growth Stocks To Buy and Hold Forever

These three companies have a high 5-year dividend yield, providing long-term stability while maximizing income.

Barchart

How Is AbbVie's Stock Performance Compared to Other Pharmaceuticals Stocks?

AbbVie has outperformed the Pharmaceuticals industry over the past year, and analysts are moderately optimistic about the stock’s prospects.

Barchart

Build a Bulletproof Dividend Portfolio With These 5 Defensive Stocks

These defensive stocks pay reliable dividends.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.